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Background: Mild parkinsonian signs (MPS) are com-
monly found during the clinical examination of older
people. These signs could reflect the accumulation of vas-
cular pathological changes in the brain. If the etiology
were vascular, one could hypothesize that individualswith
MPS would bemore likely to have systemic vascular dis-
ease than would their counterparts without these signs.
Objectives:To examinewhetherMPS are associatedwith
a history of vascular disease andwhether certainMPS (ri-
gidity, changes in axial function) are more strongly as-
sociated with a history of vascular disease than are other
MPS (tremor).
Methods: Evaluation of older people without demen-
tia in Washington Heights-Inwood, northern Manhat-
tan, NY. The presence of vascular diseases was assessed
with a structured health interview.
Results: Mild parkinsonian signs were present in 375
(16.4%) of 2286 participants without dementia. Diabe-
tes mellitus, heart disease, peripheral vascular disease,
and stroke weremore prevalent in participants withMPS
than without MPS, whereas nonvascular diseases (can-
cer, thyroid disease) were not. In a logistic regression
analysis that adjusted for age, sex, education, and de-
pressive symptoms, the number of vascular diseases was
associated with MPS (odds ratio, 1.31 [95% confidence
interval, 1.18-1.46]; P!.001). The combination of dia-
betesmellitus and heart disease increased the odds ofMPS
by 70% and the combination of these with stroke in-
creased the odds by 332%.
Conclusions: The presence of MPS in elderly individu-
als might reflect, in part, the accumulation of vascular
pathological changes in the basal ganglia or white mat-
ter regions caused by preventable vascular diseases. Pro-
spective and pathological studies are needed to further
explore this finding.
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P ARKINSONIAN-LIKE SIGNS (RI-gidity, bradykinesia) arecommonly found during theclinical examination of olderpeople who do not have
known neurological disease.1-4 It is un-
clear whether these mild parkinsonian
signs (MPS) reflect an age-associated de-
cline in nigrostriatal dopaminergic activ-
ity, the early development of degenera-
tive abnormalities in the basal ganglia, or
the accumulation of vascular pathologi-
cal changes in the basal ganglia or sub-
cortical (whitematter) regions.1-5 There is
some evidence to support a role for vas-
cular pathological changes, particularly in
the development of certainMPS (ie, rigid-
ity and gait disturbance).6-9 Vascular patho-
logical changes in the brain (subcortical
whitematter changes, lacunar infarcts) of-
ten occur in the setting of systemic vas-
cular disease or risk factors for such dis-
ease (eg, hypertension, diabetesmellitus).
If the etiology of MPS were vascular, one
might hypothesize that individuals with
MPS would be more likely to have evi-
dence of systemic vascular disease when
compared with their counterparts with-
out these signs.
The current study was conducted in
community-dwelling older people with-
out dementia living in Washington
Heights-Inwood, northernManhattan,NY,
who had an examination between 1999
and 2001. The goal of this report was to
examinewhetherMPS are associated with
a history of vascular disease and whether
certain MPS (rigidity, changes in axial
function) aremore strongly associatedwith




Study participants were drawn by random
sampling of healthy Medicare beneficiaries
who were 65 years and older and resided
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within a geographically defined area of northern Manhat-
tan.10 The cohort represents a combination of continuing
members of a cohort originally recruited in 1992 and mem-
bers of a new cohort recruited between 1999 and 2001;
approximately one quarter of the sample was from the origi-
nal 1992 cohort and three quarters, from the new cohort.
Recruitment of all participants was initially achieved by con-
tacting a stratified random sample of 50% of all persons 65
years and older obtained from the Health Care Finance
Administration (Center for Medicare Services).10 As of July
1, 2004, data were available on 2776 participants who were
evaluated between 1999 and 2001 (for the original 1992
cohort, this represented their third follow-up assessment,
and for the new cohort, this represented their baseline
assessment).10 The mean (SD) age of the 2776 participants
was 78.2 (7.1) years; 1886 (67.9%) were women and 1098
(39.6%) were Hispanic. Their mean (SD) education was 9.9
(4.9) years.
A trained research assistant administered a structured
interview of health. This included demographic questions
and questions on the presence or absence (either currently
or in the past) of hypertension, diabetes mellitus, heart dis-
ease (including myocardial infarction, congestive heart fail-
ure, or other heart conditions), peripheral vascular disease,
stroke, chronic obstructive pulmonary disease, thyroid dis-
ease, liver disease, renal disease, peptic ulcer disease, cancer,
arthritis, head injury with loss of consciousness, and sei-
zures. Systolic and diastolic blood pressures were measured
by the assistant. Each participant also underwent a standard-
ized neurological examination, which included an abbrevi-
ated (10-item) version of the motor portion of the Unified
Parkinson’s Disease Rating Scale (UPDRS).11 We assigned a
diagnosis of Parkinson disease (PD) or Parkinson plus syn-
drome based on research criteria12 and participants were
considered to have PD or Parkinson plus syndrome if (1)
they had previously received a diagnosis of PD or Parkinson
plus syndrome, or (2) they had 2 or more cardinal signs of
parkinsonism on the standardized neurological examination.
Cardinal signs were rest tremor, rigidity, bradykinesia, and
changes in posture. For the diagnosis of PD or Parkinson
plus syndrome, a cardinal sign was considered to be present
when 1 UPDRS rating was 2 or higher. There were 8 partici-
pants with 1 cardinal sign and either (1) increased tone in
the setting of upper motor neuron signs (eg, participants
with a history of a symptomatic stroke with residual weak-
ness or participants with multiple sclerosis) or (2) stooped
posture due to severe musculoskeletal problems (eg, kypho-
sis, scoliosis); they were not diagnosed with PD. Thirty-two
participants (1.2%) had a diagnosis of PD or Parkinson plus
syndrome, which is consistent with a prevalence of PD that
has been reported for persons 65 years and older in northern
Manhattan.13
We excluded 490 participants for the following reasons. The
32 participants with PD or Parkinson plus syndrome were ex-
cluded because our intention was to study a community popu-
lation of older people without these diseases. We also ex-
cluded 330 participants because they had dementia; this would
lessen the validity of their response to questions about medi-
cal conditions. Participants with incomplete UPDRS data
(n=128) were excluded as well. Parkinsonian signs can result
from the use of neuroleptic medications, but none of the re-
maining participants were taking these. The final sample, 2286
participants, had amean (SD) age of 77.2 (6.6) years and amean
(SD) education of 10.3 (4.8) years; 1535 (67.1%) were women
and 844 (36.9%) were Hispanic. The study was approved by
our institution’s internal review board andwritten consent was
obtained from all participants.
NEUROLOGICAL EVALUATION
The 10-item version of the motor portion of the UPDRS in-
cluded evaluations of speech, facial expression, tremor at rest
(in any body region), rigidity (rated separately in the neck, right
arm, left arm, right leg, and left leg), changes in posture, and
body (axial) bradykinesia.10 Each of the 10 itemswas rated from
0 to 4. The generalmedical doctors who administered themodi-
fied motor portion of the UPDRS were trained using a struc-
tured protocol, as documented elsewhere.10
As in previous analyses,10MPSwere defined as present when
any 1 of the following conditionswasmet: (1) 2 ormoreUPDRS
ratings of 1, (2) 1 UPDRS rating of 2 or higher, or (3) a UPDRS
rest tremor rating of 1. Based on a factor analysis, MPS were
stratified into 3 MPS subscores: axial function (changes in
speech, facial expression, changes in posture, and axial brady-
kinesia), rigidity, and tremor.10,14 An abnormality in axial func-
tion was considered present when the participants had either
(1) UPDRS ratings of 1 in 2 or more items or (2) 1 UPDRS rat-
ing of 2 or higher. Rigidity was considered present when the
participants had either (1)UPDRS ratings of 1 in 2 ormore items
or (2) 1 UPDRS rating of 2 or higher. Tremor was considered
present when the participants had a UPDRS rest tremor rating
of 1.10
All participants underwent a standardized neuropsycho-
logical battery.15 The neuropsychological battery was de-
signed to assess cognitive functions that are typically affected
in dementia15 and includedmeasures of learning andmemory,
orientation, abstract reasoning, language, and visuospatial abil-
ity. Participants were considered to have dementia if they met
established criteria.16 As noted earlier, the 330 participants who
met inclusion criteria for dementia were excluded. A designa-
tion of mild cognitive impairment required (1) objective im-
pairment in at least 1 of 4 cognitive domains (memory, execu-
tive function, language, and visuospatial) based on performance
on the neuropsychological test battery and a 1.5-SD cutoff for
a domain score using normative corrections for age, years of
education, ethnicity, and sex, (2) a subjective complaint of
memory impairment, and (3) absence of functional impair-
ment, according to published criteria.17,18
Depressive symptomswere assessed and rated with a 9-item
version of the Center for Epidemiologic Studies Depression
(CES-D) Scale,19 in which individuals reported symptoms of
depression (range, 0 [no depressive symptoms] to 9 [maximal
depressive symptoms]).
STATISTICAL ANALYSES
Analyses were conduced in SPSS version 11.0. Differences in
categorical variables were assessed with "2 tests and differ-
ences in continuous variables, with either t tests or analysis of
variance. We grouped diseases into vascular diseases (ie, dis-
eases that are often associatedwithpathological vascular changes:
hypertension, diabetes mellitus, heart disease, peripheral vas-
cular disease, stroke) vs nonvascular diseases (eg, cancer, chronic
obstructive pulmonary disease, thyroid disease).
In unadjusted and then adjusted logistic regression analy-
ses,we examined the associations betweenMPS (dependent vari-
able) and reported vascular diseases, with each vascular dis-
ease being an independent variable in a separate logistic
regressionmodel. This resulted in odds ratios (ORs) with 95%
confidence intervals (CIs). In unadjusted and then adjusted lo-
gistic regression analyses, we examined the associations be-
tween different MPS subscores (changes in axial function, ri-
gidity, tremor) and reported vascular diseases,with each vascular
disease being an independent variable in a separate logistic re-
gression model. In adjusted analyses, we considered the fol-
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lowing confounders based on our own analyses in this data set
as well as published literature1-4,10: age in years, sex, years of
education, CES-D score, and history of arthritis. In 1 set of analy-
ses, we defined MPS as being present when any UPDRS rating
was 1 or higher and absent when all UPDRS ratings were 0; the
goal of these analyses was to increase power for association. In
several analyses, we excluded participants with reported stroke
because stroke can result in spasticity, which on examination,
can be difficult to distinguish from increased tone in the set-
ting of rigidity. For other analyses, the number of reported vas-
cular diseases was summed. In a secondary analysis, we de-
fined hypertension based on history and examination (reported
hypertension by history or a systolic blood pressure #140
mm Hg or a diastolic blood pressure #90 mm Hg).
RESULTS
Mild parkinsonian signs were present in 375 (16.4%) of
2286 participants without dementia. Mild parkinsonian
signs included changes in axial function (168 partici-
pants [7.3%]), rigidity (221 [9.7%]), and tremor (93
[4.1%]). The 375 participants with MPS were older and
had fewer years of education than the 1911 participants
without MPS (Table 1).
Participants with MPS differed from their counter-
parts without MPS in terms of the proportions with vas-
cular diseases, even after excluding participants with
stroke; the 2 groups did not differ with respect to the pro-
portions with most nonvascular diseases (Table 2). In
logistic regression analyses (Table 3), we examined the
associations betweenMPS (dependent variable) and vas-
cular diseases, with each vascular disease being an inde-
pendent variable in a separate logistic regression model.
Mild parkinsonian signs were associated with diabetes
mellitus, heart disease, peripheral vascular disease, and
stroke; after excluding participants with stroke, the re-
sults were similar. The combination of diabetes mellitus
and heart disease (vs neither) was associatedwith an 86%
increased odds of MPS (OR, 1.86 [95% CI, 1.23-2.80];
P=.003), and the combination of diabetes mellitus, heart
disease, and stroke (vs none of these) was associatedwith
a 450% increase in odds ofMPS (OR, 4.50 [95%CI, 2.07-
9.77]; P!.001) in unadjusted models. In a logistic re-
gression analysis that adjusted for age, sex, education,
CES-D score, and arthritis, the results were similar; the
combination of diabetes mellitus and heart disease (vs
neither)was associatedwith a 70% increased odds ofMPS
(OR, 1.70 [95% CI, 1.10-2.62]; P=.02), and the combi-
nation of diabetes mellitus, heart disease, and stroke (vs
none of these) was associated with a 332% increase in
odds of MPS (OR, 3.32 [95% CI, 1.47-7.52]; P=.004).
The number of vascular diseases was higher in par-
ticipants with MPS compared with those without MPS
(mean [SD], 1.61 [1.10] vs 1.25 [1.02]; P!.001), even
after excluding participants with stroke (mean [SD], 1.37
[0.99] vs 1.15 [0.93]; P!.001). In a logistic regression
analysis that adjusted for age, sex, education,CES-D score,
and arthritis, the number of vascular diseases was asso-
ciated with MPS (OR, 1.31 [1.18-1.46]; P!.001) (ie, for
each reported vascular disease, the odds of having MPS
increased by 31%). In thismodel, theOR for agewas 1.08
(95% CI, 1.06-1.10) (P!.001). In an additional logistic
regression analysis that adjusted for age, sex, education,
CES-D score, and arthritis and that excluded all partici-
pants with stroke and mild cognitive impairment, the
number of vascular diseaseswas associatedwithMPS (OR,
1.23 [95% CI, 1.05-1.45]; P=.01).
The number of nonvascular diseaseswas similar in par-
ticipants with MPS compared with those without MPS
(mean [SD], 1.04 [0.86] vs 1.01 [0.92]; P=.49). In an
adjusted logistic regression analysis, the number of non-
vascular diseases was not associated withMPS (OR, 0.96
[95% CI, 0.81-1.14]; P=.64).
A similar proportion of participantswith vs thosewith-
out MPS had a history of hypertension (Table 2). In a
secondary analysis, we defined hypertension based onhis-
tory and examination; hypertension was present in 315
(84.0%) of 375 participants with MPS vs 1506 partici-
pants (78.8%) without MPS ("2=5.22; P=.02).
In adjusted logistic regression analyses, we exam-
ined the associations between different MPS subscores
(changes in axial function, rigidity, tremor) and the num-
ber of reported vascular and nonvascular diseases; the
number of reported vascular diseases was most strongly
associated with rigidity (Table 4).
COMMENT
Vascular diseases were more common in community-
dwelling elderly individuals with MPS compared with
those without MPS, and in adjusted analyses, for each
reported vascular disease, the odds of having MPS
increased by 31%. The presence of vascular disease was
most strongly associated with the presence of rigidity on
examination.
These results suggest that the presence of MPS in el-
derly individuals might reflect, at least in part, the con-
sequences of systemic vascular disease on the brain. The
most likely mechanism is the accumulation of vascular
pathological changes in either the basal ganglia or sub-
cortical white matter regions (ie, the possible disrup-
tion of neural connections between the frontal cortex,
Table 1. Demographic and Clinical Characteristics
of 2286 Participants Stratified by Presence or Absence






Age, y, mean (SD) 80.2 (7.0)* 76.4 (6.4)
Female, No. (%) 240 (64.0) 1295 (67.8)
Ethnicity, No. (%)
Non-Hispanic white 120 (32.0) 563 (29.5)
Non-Hispanic African American 121 (32.3) 605 (31.7)
Hispanic 130 (34.7) 714 (37.4)
Other 4 (1.1) 29 (1.5)
Education, y, mean (SD) 9.8 (4.7)† 10.5 (4.8)
CES-D score, mean (SD) 2.9 (1.5)† 2.7 (1.4)
Mild cognitive impairment, No. (%)‡ 114 (30.9) 494 (26.5)
Cigarette smoker, No. (%) 45 (12.0) 196 (10.3)
Abbreviation: CES-D, Center for Epidemiologic Studies Depression Scale.
*P!.001.
†P!.05.
‡Data were missing on 56 participants.
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OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Hypertension 1.24 (0.98-1.57);
1.24 (1.02-1.51)
.07; .03 1.17 (0.91-1.50) .21 1.06 (0.81-1.39) .65
Diabetes mellitus 1.34 (1.02-1.76);
1.34 (1.06-1.68)
.04; .01 1.37 (1.03-1.82) .03 1.34 (0.98-1.84) .07
Heart disease 1.52 (1.20-1.92);
1.64 (1.34-2.00)
.001; !.001 1.33 (1.04-1.70) .02 1.35 (1.02-1.77) .04
Peripheral vascular disease 1.42 (1.06-1.90);
1.61 (1.26-2.06)
.02; !.001 1.29 (0.95-1.76) .08 1.45 (1.03-2.03) .03
Stroke 3.41 (2.48-4.69);
3.39 (2.51-4.58)
!.001; !.001 3.30 (2.37-4.59) !.001 NA
Abbreviations: CES-D, Center for Epidemiologic Studies Depression Scale; CI, confidence interval; NA, not applicable; OR, odds ratio; UPDRS, Unified
Parkinson’s Disease Rating Scale.
*The OR for the association between MPS and treated hypertension was 1.24 (95% CI, 0.99-1.56) (P = .06). The OR for the association between MPS and
treated diabetes mellitus was 1.21 (95% CI, 0.91-1.62) (P = .19).
†For each disease, the second set of data represents the results of analyses in which MPS were defined as present when any UPDRS rating was 1 or higher
(n = 641 or 28.0% of participants) and absent when all UPDRS ratings were 0.
‡Adjusted for age in years, sex, years of education, CES-D score, and arthritis.
Table 4. Associations Between Number of Vascular Diseases and Mild Parkinsonian Signs (MPS) Subscores
in Adjusted Logistic Regression Analyses*
Changes in Axial Function Rigidity Tremor
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
No. of vascular diseases
All participants 1.19 (1.02-1.38) .03 1.35 (1.18-1.53) !.001 1.14 (0.94-1.39) .19
Excluding participants with stroke 1.13 (0.93-1.37) .21 1.24 (1.05-1.46) .01 1.18 (0.93-1.50) .16
No. of nonvascular diseases 0.97 (0.76-1.22) .77 0.95 (0.77-1.17) .61 0.67 (0.46-0.97) .03
Abbreviations: CES-D, Center for Epidemiologic Studies Depression Scale; CI, confidence interval; OR, odds ratio.
*Adjusted for age in years, sex, years of education, CES-D score, and arthritis.
Table 2. Presence or Absence of Vascular vs Nonvascular Diseases in Participants Stratified by Presence or Absence
of Mild Parkinsonian Signs (MPS)
All Participants, No. (%)
Excluding Participants










Hypertension 252 (67.2) 1188 (62.2) 194 (63.6) 1094 (61.1)
Diabetes mellitus 83 (22.3)* 336 (17.7) 66 (21.8)* 306 (17.2)
Heart disease 128 (34.1)† 487 (25.5) 98 (32.1)† 428 (23.9)
Peripheral vascular disease 68 (18.1)* 258 (13.5) 57 (18.7)† 226 (12.6)
Stroke 70 (18.9)‡ 121 (6.4) 0 0
Nonvascular diseases
Chronic obstructive pulmonary disease 40 (10.7) 197 (10.3) 37 (12.1) 180 (10.1)
Thyroid disease 40 (10.7) 182 (9.5) 30 (9.8) 169 (9.4)
Liver disease 2 (0.5) 35 (1.8) 2 (0.7) 30 (1.7)
Renal disease 4 (1.1) 23 (1.2) 3 (1.0) 21 (1.2)
Peptic ulcer disease 36 (9.6) 203 (10.6) 29 (9.5) 177 (9.9)
Cancer 37 (9.9) 205 (10.7) 29 (9.5) 184 (10.3)
Arthritis 219 (58.4)* 1007 (52.7) 180 (59.0)* 943 (52.7)
Head injury with loss of consciousness 9 (2.4) 57 (3.0) 6 (2.0) 53 (3.0)
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thalamus, and the striatum). One possibility is that these
accumulated vascular pathological changes take the form
of strokes (ie, stroke as a mediator of the association be-
tween vascular risk factors andMPS). However, our find-
ing in some analyses that removal of participants with
stroke did not appreciably change the magnitude of the
associations between hypertension, diabetes, and MPS
(Table 3) suggests that accumulated vascular pathologi-
cal changes might not be in the form of clinically appar-
ent strokes.
It is well-known that “vascular pseudoparkinson-
ism” can occur in the setting of basal ganglia infarcts or
deep white matter ischemic lesions.6,7,20-22 These pa-
tients typically have moderate to severe gait disturbance
as well as rigidity and bradykinesia in the absence of rest
tremor.6,7,20 Yet there have been few (2) studies examin-
ing vascular risk factors or vascular disease and their as-
sociation with MPS in normal elderly cohorts with only
mild parkinsonism. In the first study,8 which included
elderly subjects whose Mini-Mental State Examination
score was lower than the expected age- and education-
specific value, participants with rigidity and gait distur-
bance were compared with participants without these
characteristics; participants with rigidity and gait distur-
banceweremore likely to havehypertension and lowhigh-
density lipoprotein cholesterol levels, although the 2
groups did not differ with regard to the proportions with
diabetesmellitus, obesity, smoking cigarettes, or high low-
density lipoprotein cholesterol levels. In the second study,9
the relation between diabetesmellitus and parkinsonian-
like signs was assessed prospectively and longitudinally
in 822 older Catholic clergymen andwomenwithout PD
or dementia; the investigators found that diabetes was
associated with progression of rigidity and gait distur-
bance. Overall, these 2 studies suggest that some vascu-
lar diseases are associated with MPS and the progres-
sion of MPS.
Althoughwe found an association between several vas-
cular diseases and MPS, we did not find a consistent as-
sociation between MPS and hypertension (ie, the asso-
ciation betweenMPS and hypertensionwas only apparent
on a secondary analysis). One possible explanation is the
high prevalence of this condition in our sample. If the
sample is too homogeneous in terms of a history of hy-
pertension, finding a relation between hypertension and
MPS may not be possible, even if it exists. In addition,
our definition of hypertension did not take into account
its duration and severity. Persons with more severe and
longer-durationhypertension aremore likely to have heart
disease, peripheral vascular disease, and stroke. The er-
ror in the ascertainment of hypertension and its high
prevalence in our sample likely biased our estimates of
the association between hypertension and MPS toward
the finding of no association. Better measurements of hy-
pertension severity, such as left ventricular hypertro-
phy ascertained by electrocardiogram or echocardio-
gram, may be needed to assess this association.
Our study has several limitations. We ascertained
vascular disease by self-report and lacked subclinical
measurement of disease such as glycosylated hemoglo-
bin measurement for diabetes, electrocardiogram or
echocardiography for heart disease, brain imaging for
stroke, and vascular studies for peripheral vascular
disease. This is likely to result in an underestimation
of the true prevalence of these conditions and, assum-
ing nondifferential misclassification by MPS, resulted
in underestimation of the associations that we report.
Second, our analyses were cross-sectional, and this
limits the inferences that can be made about the causal
nature of the association of history of vascular disease
and MPS. A prospective study, which is under way,
will examine this issue. We also plan a study using
brain magnetic resonance imaging to determine
whether indeed MPS are more common in individuals
with vs those without evidence on imaging of vascular
pathological changes in the brain. Third, our modified
UPDRS did not include the assessment of appendicu-
lar (limb) bradykinesia so it is possible that we may
have underestimated the correlates of MPS. Fourth, it
can be difficult in elderly persons and persons with
dementia to distinguish paratonia from true rigidity.
Therefore, in our analyses, we excluded all partici-
pants with dementia. For some analyses, we also
excluded participants with reported stroke because
stroke can result in spasticity, which on examination,
can be difficult to distinguish from increased tone in
the setting of rigidity. Despite these limitations, the
study had several strengths, including the use of a
community-based sample, the size of the sample
(#2000 elderly participants), and the adjustment for
potential demographic and medical confounders.
In summary, the presence of MPS, and rigidity in par-
ticular, in elderly individuals might reflect, in part, the
accumulation of vascular pathological changes in the basal
ganglia or white matter regions caused by preventable
vascular disease. Prospective studies as well as imaging
and pathological studies are needed to further explore
this finding.
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